Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
Open Access
- 17 July 2025
- journal article
- laboratory science
- Published by Wiley in Haemophilia
- Vol. 31 (5) , 1092-1102
Abstract
Background: Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown. Objectives: To estimate FVIIIeq of emicizumab using global assays of haemostasis. Patients/Methods: We sampled plasma from (1) PWHA of all severities and therapeutic regimens and (2) persons with severe haemophilia A on emicizumab. Thrombin generation assay (TGA) and clot formation and lysis assay (CLA) were measured by commercially available (Technothrombin, Technoclone) and turbidimetric assays, respectively. FVIII was measured by a chromogenic (CSA) and emicizumab by a modified one‐stage assay (OSA). Using principal components (PC) or individual parameters as dependent and independent variables in linear regression with (1) FVIII and (2) emicizumab levels, respectively, we estimated FVIIIeq (95% CI) of emicizumab. Results: We collected 253 samples from 110 PWHA and 41 samples from nine individuals on emicizumab prophylaxis. TGA parameters of emicizumab‐treated subjects clustered distinctly, with no correlation amongst samples with only endo‐/exogenous FVIII. Consequently, FVIIIeq varied substantially between parameters: Using individual TGA parameters, endogenous thrombin potential (ETP) and thrombin peak resulted in conversion factors of 0.85 (0.60–1.24) and 0.25 (0.15–0.37) IU/dL FVIIIeq per µg/mL emicizumab, respectively. CLA parameters showed broader overlap, with an FVIIIeq estimate of 0.82 (0.44–1.38). Conclusion: Distinct clustering of emicizumab and FVIII samples in TGA leads to conflicting FVIIIeq estimates between parameters, highlighting systematic limitations and questioning their clinical usefulness. A, possibly conservative, FVIIIeq conversion factor estimate as determined by the thrombin peak could range from 0.15 to 0.37.Keywords
This publication has 38 references indexed in Scilit:
- International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodologyJournal of Thrombosis and Haemostasis, 2024
- Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia AJournal of Thrombosis and Haemostasis, 2024
- In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumabThrombosis Research, 2023
- Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patientsInternational Journal of Hematology, 2022
- HaemophiliaNature Reviews Disease Primers, 2021
- Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxisInternational Journal of Hematology, 2019
- Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studyThe Lancet Haematology, 2019
- Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation AssaysThrombosis and Haemostasis, 2019
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A modelNature Medicine, 2012
- Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotypeHamostaseologie, 2010